Showing 5211-5220 of 5693 results for "".
- Fight For Sight and Prevent Blindness Announce Call for Entries for the 2020 Joanne Angle Public Health Awardhttps://modernod.com/news/fight-for-sight-and-prevent-blindness-announce-call-for-entries-for-the-2020-joanne-angle-public-health-award/2476933/National non-profit organizations Fight for Sight and Prevent Blindness are announcing a call for applications for the Joanne Angle Public Health Award, a $25,000 grant to support a public health research project seeking to put an end to unnecessary vision loss. The award was named for Ms
- Topline Results From Phase 2 Trial Show Nicox’s Glaucoma Drug Candidate NCX 470 Meets Primary Endpointhttps://modernod.com/news/topline-results-from-phase-2-trial-show-nicoxs-glaucoma-drug-candidate-ncx-470-meets-primary-endpoint/2476931/Nicox SA announced positive topline results from its US multicenter, Dolomites dose-response phase 2 clinical trial evaluating investigational NCX 470, a novel second-generation nitric oxide (NO)-donating bimatoprost analog, compared to latanoprost ophthalmic solution 0.005% in 433 patients with
- Johnson & Johnson Vision Care Introduces Acuvue RevitaLens Multi-Purpose Disinfecting Solutionhttps://modernod.com/news/johnson-johnson-vision-care-introduces-acuvue-revitalens-multi-purpose-disinfecting-solution/2476925/Johnson & Johnson Vision has unveiled the first extension of the Acuvue brand name beyond contact lenses with the launch of Acuvue RevitaLens Multi-Purpose Disinfecting Solution (MPDS). Acuvue RevitaLens MPDS delivers disinfection and all-day comfort for reusable contact lens wearers. Its dua
- DORC Obtains 510k Clearance for Launch of EVA Upgrade Enhancementshttps://modernod.com/news/dorc-obtains-510k-clearance-for-launch-of-eva-upgrade-enhancements/2476922/DORC has announced 510(k) clearance for a range of enhancements to the EVA surgical system. The enhancements has been developed in close collaboration with surgeons and deliver both OR efficiency and surgical performa
- EyePoint Pharmaceuticals Announces Yutiq Presentations at AAO Annual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-yutiq-presentations-at-aao-annual-meeting/2476921/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for presentation at the American Aca
- Eversight to Offer Preloaded DMEK in DORC Tubehttps://modernod.com/news/eversight-first-to-offer-preloaded-dmek-in-dorc-tube/2476911/Eversight announced it is the first eye bank to prepare preloaded Descemet membrane endothelial keratoplasty (DMEK) tissue in the Melles DORC tube, offering corneal surgeons more preloaded tissue options that further streamline surgeries and reduce cost, according to a company news release. <
- Sifi Appoints New Country Manager for Italyhttps://modernod.com/news/sifi-appoints-new-country-manager-for-italy/2476904/Sifi has announced that Fabrizio Folco has joined the company as “Country Manager Italy,” and will be responsible for accelerating company development on the Italian market through management of the company’s commercial strategy and organization, for both pharma and surgical are
- US House Speaker Nancy Pelosi Introduces Plan to Permit Price Negotiation for Some Drugshttps://modernod.com/news/us-house-speaker-nancy-pelosi-introduces-plan-to-permit-price-negotiation-for-some-drugs/2476901/US House Speaker Nancy Pelosi on Thursday unveiled proposed legislation that would permit the federal government to negotiate prices of drugs for Medicare and other health programs. Specifically, the proposal would empower the Department of Health and Human Services (HHS) to annually ne
- Eye Cancer Researchers at Bascom Palmer and Sylvester Identify Function of Key Tumor Suppressorhttps://modernod.com/news/eye-cancer-researchers-at-bascom-palmer-and-sylvester-identify-function-of-key-tumor-suppressor/2476900/Cancer cells remember things they shouldn’t. During development, stem and progenitor cells move freely through the body as they differentiate into heart, brain, liver, and eyes. But after humans are born, that process should stop. Cells shouldn’t travel or change anymore; they should stay put and
- Vertical Pharmaceuticals Announces Submission of New Drug Application for RVL-1201https://modernod.com/news/vertical-pharmaceuticals-announces-submission-of-new-drug-application-for-rvl-1201/2476894/Vertical Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced the submission of a new drug application (NDA) to the FDA for approval of RVL-1201 (RVL) for the treatment of acquired blepharoptosis (droopy eyelid). RVL is a novel, once-daily ophthalmic formulation of oxymeta